Man Group’s AbCellera Biologics ABCL Stock Holding History

Man Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	+228,979	New	+$1.12M	﹤0.01%	1617
2024 Q2	–	Sell	-771,934	Closed	-$3.5M	–	2002
2024 Q1	$3.5M	Buy	+771,934	New	+$3.94M	0.01%	1109
2023 Q1	–	Sell	-305,478	Closed	-$3.09M	–	2054
2022 Q4	$3.09M	Sell	305,478 -359,944	-54%	-$4.16M	0.01%	1010
2022 Q3	$6.58M	Buy	+665,422	New	+$7.3M	0.03%	635
2022 Q2	–	Hold	0	–	–	–	1128
2021 Q4	–	Sell	-49,165	Closed	-$985K	–	1927
2021 Q3	$985K	Buy	49,165 +3,308	+7%	+$58.5K	﹤0.01%	1340
2021 Q2	$1.01M	Buy	45,857 +552	+1%	+$15.2K	﹤0.01%	1393
2021 Q1	$1.54M	Buy	+45,305	New	+$1.8M	0.01%	1184

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Man Group's ABCL Position: Q2 2026 in Review

Man Group opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 228,979 shares worth $1.8M. The stake represents ﹤0.01% of the portfolio and ranks #1617 among its holdings. This is a return to the name: Man Group previously reported a position in ABCL as recently as Q1 2024.

Man Group first reported a position in ABCL in Q1 2021 and has held it in 7 quarters since. The position peaked at $6.58M in Q3 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Man Group held 228,979 shares of AbCellera Biologics worth $1.8M as of Q2 2026.
AbCellera Biologics was a new Man Group position in Q2 2026.
AbCellera Biologics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1617 holding.
Man Group first reported a position in AbCellera Biologics in Q1 2021 and has held it in 7 quarters since.
Man Group's AbCellera Biologics position peaked at $6.58M in Q3 2022.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.